CGON • NASDAQ
CG Oncology, Inc. Common stock
$54.20
Stock Details
| Market Cap | 4,063,131,021 |
|---|---|
| Day Change | 12.27 (29.26%) |
| Volume | 6,958,295 |
| Avg Volume | 886,704 |
| Price Range | 14.8-57.395 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Financial Overview
| 52 Week High | 46.01 |
|---|---|
| 52 Week High Date | 2025-12-05 |
| 52 Week Low | 14.8 |
| 52 Week Low Date | 2025-04-09 |
| 10D Avg Trading Vol | 0.84021 |
| YTD Price Return Daily | 0.9875 |
| MTD Price Return Daily | 0.9875 |
Cash Flow
| TTM/Share | |
|---|---|
| Annual/Share | -1.0367 |
| Quarterly/Share | -1.4963 |
Price-to-Earnings
| Annual Ratio | 35.2962 |
|---|---|
| Quarterly Ratio | 22.7919 |
| TTM |
Revenue
| 3Y Growth | -52.09 |
|---|---|
| 5Y Growth | |
| Annual/Share | 3774.42 |
| TTM/Share | 0.0283 |
| 5Y Share Growth |
Earnings Per Share
| Annual | -1.4087 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 4.9187 |
|---|---|
| Annual Ratio | 2.9267 |
| TTM | 4.4663 |